A new 10–15 minute series aims to bring clarity and nuance to the big and bold ideas shaping the future of human longevity.
Longevity.Technology has launched Longevity Bites, a new segment running alongside its flagship podcast, Longevity.Technology UNLOCKED. The format is simple on paper: ten to fifteen minutes, one topic, explained properly. In practice, it’s the company’s answer to a gap CEO Phil Newman says he kept running into.
“I really like to balance every side of an argument and share my conclusions via longevity technology, conference platforms and the great team that I work with,” Newman said, describing the thinking behind the new series. The field, he argues, has a habit of splitting into two camps – breathless hype on one side, dense academic papers on the other – with very little sitting in between for people who just want a straight, well-reasoned answer.
Newman is hosting the first run of episodes himself, styled loosely on the way other channels distill complicated ideas into something watchable in a coffee break. The opening episode, Will AI Make Death Optional?, takes on one of the biggest questions in the field head-on.
It’s a question that usually gets a lazy answer in one direction or the other. Newman doesn’t take either. He opens by pointing out that a claim like this would have been “laughed out of any serious biology department 20 years ago,” before making the case for why it deserves a real hearing today. Aging, he explains, has quietly been reclassified in scientific circles, not as a fixed fact of biology, but as a process, and “processes can, in principle, be slowed, stopped or even reversed.”
From there, the episode gets specific about where AI is actually moving the needle. Drug discovery has historically taken over a decade to find out whether a single molecule works. Newman points to Insilico Medicine’s AI-designed lung disease treatment, which went from concept to Phase 2 human trials in under 30 months – roughly a fifth of the usual timeline. He pairs that with the rise of “aging clocks,” tools that read blood, DNA and other biomarkers to estimate how old the body is, allowing researchers to check whether a treatment is working in months instead of decades.
However, the episode doesn’t stop at the exciting part, which is where it earns its credibility.
“Aging is not one disease with one cause,” Newman says, walking through the roughly dozen interacting systems involved – mitochondria losing efficiency, the immune system weakening, cells piling up damage faster than the body can clear it. AI can design a candidate molecule overnight, he notes, but it can’t make the underlying trade-offs disappear. As he puts it, tackling the deeper limitation head-on: “biology runs on biology’s clock. AI runs on silicon’s clock.”
So where does the episode land on its own headline question? Newman’s answer is what he calls “a specific kind of no,” not a dismissal, but a more precise claim than the field usually gets credit for. AI isn’t switching aging off. What it is doing, he argues, is shrinking the gap between having an idea for slowing a piece of aging and actually knowing whether that idea works in a human body. “That is not nothing,” he says.
It’s a fitting tone for the series to launch on: honest about the limits, genuinely excited about the progress and allergic to the hype cycle the field has been through before.
New episodes of Longevity Bites will land alongside the regular Longevity.Technology UNLOCKED lineup. You can stream our first one now on Apple Podcasts, Spotify and YouTube. Subscribe for more Longevity Bites, where Phil Newman breaks down the science, ideas, and emerging technologies shaping the future of human longevity.
